Extraintestinal manifestations and complications in inflammatory bowel diseases

World Journal of Gastroenterology

Volumn 12, Issue 30, 2006, Pages 4819-4831

  Rothfuss, Katja S ^a   Stange, Eduard F ^a   Herrlinger, Klaus R ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Complications; Crohn's disease; Extraintestinal manifestations; Inflammatory bowel diseases; Therapy; Ulcerative colitis

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DAPSONE; ETIDRONIC ACID; FOLIC ACID; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISOLONE; RISEDRONIC ACID; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; THALIDOMIDE; TRAMADOL; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D;

ACNE; ACUTE PANCREATITIS; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTHROPATHY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC INFLAMMATION; CHRONIC PANCREATITIS; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DRUG ERUPTION; ENTERITIS; EPISCLERITIS; ERYTHEMA NODOSUM; GLOMERULONEPHRITIS; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOENCEPHALOPATHY; LUNG DISEASE; LUNG FIBROSIS; LUNG TOXICITY; MALNUTRITION; MOON FACE; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; OSTEOMALACIA; OSTEOPOROSIS; PANCREATITIS; PATHOGENESIS; PERICARDITIS; POLYNEUROPATHY; PRIMARY SCLEROSING CHOLANGITIS; PROTEINURIA; PYODERMA GANGRENOSUM; REVIEW; SACROILIITIS; SKIN ATROPHY; SKIN DEFECT; STOMATITIS; SYMPTOM; THROMBOEMBOLISM; ULCERATIVE COLITIS; UVEITIS;

EID: 33748319730     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i30.4819     Document Type: Review

References (137)

1. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-1122
2. Ricart E, Panaccione R, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004; 10: 207-214
3. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827-836
4. Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Diaz-Rubio M. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis. Med Clin (Barc) 2005; 125: 297-300
5. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology 1994; 107: 103-108
6. Oshitani N, Watanabe K, Nakamura S, Higuchi K, Arakawa T. Extraintestinal complications in patients with ulcerative colitis. Nippon Rinsho 2005; 63: 874-878
7. Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut 1996; 38: 738-741
8. Roussomoustakaki M, Satsangi J, Welsh K, Louis E, Fanning G, Targan S, Landers C, Jewell DP. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112: 1845-1853
9. Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002; 123: 714-718
10. Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000; 118: 274-278
11. Mallas EG, Mackintosh P, Asquith P, Cooke WT. Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27 (W27). Gut 1976; 17: 906-910
12. van Milligen de Wit AW, van Deventer SJ, Tytgat GN. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol 1995; 90: 893-900
13. Peeters H, Vander Cruyssen B, Laukens D, Coucke P, Marichal D, Van Den Berghe M, Cuvelier C, Remaut E, Mielants H, De Keyser F, Vos MD. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis 2004; 63: 1131-1134
14. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55: 401-412
15. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-391
16. Orchard TR, Dhar A, Simmons JD, Vaughan R, Welsh KI, Jewell DP. MHC class I chain-like gene A (MICA) and its associations with inflammatory bowel disease and peripheral arthropathy. Clin Exp Immunol 2001; 126: 437-440
17. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res 2002; 46: 1-6
18. de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27: 2860-2865
19. Mielants H, Veys EM, De Vos M, Cuvelier C, Goemaere S, De Clercq L, Schatteman L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995; 22: 2266-2272
20. Maugars Y, Mathis C, Berthelot JM, Charlier C, Prost A. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol 1996; 35: 767-770
21. Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M, Tonelli F, Matucci-Cerinic M. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004; 63: 1664-1669
22. Peloso PM, Braun J. Expanding the armamentarium for the spondyloarthropathies. Arthritis Res Ther 2004; 6 Suppl 2: S36-43
23. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62: 74-76
24. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005; 52: 1216-1223
25. Kruithof E, De Rycke L, Roth J, Mielants H, Van den Bosch F, De Keyser F, Veys EM, Baeten D. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005; 52: 3898-3909
26. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 791-794
27. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 795-799
28. Satsangi J. Compston, Osteoporosis associated with inflammatory bowel disease, in Inflammatory bowel disease. Churchill Livingstone 2003; 637-648
29. Hylander E, Ladefoged K, Madsen S. Calcium balance and bone mineral content following small-intestinal resection. Scand J Gastroenterol 1981; 16: 167-176
30. Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type I collagen in patients with inflammatory bowel disease. Gut 1996; 38: 223-228
31. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 410-415
32. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy Montbrun T, Listrat V, Dougados M, Couturier D, Amor B. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992; 37: 1396-1403
33. Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type I collagen in patients with inflammatory bowel disease. Gut 1996; 38: 223-228
34. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 228-233
35. Staun M, Tjellesen L, Thale M, Schaadt O, Jarnum S. Bone mineral content in patients with Crohn's disease. A longitudinal study in patients with bowel resections. Scand J Gastroenterol 1997; 32: 226-232
36. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93: 1483-1490
37. Hela S, Nihel M, Faten L, Monia F, Jalel B, Azza F, Slaheddine S. Osteoporosis and Crohn's disease. Joint Bone Spine 2005; 72: 403-407
38. Siffiledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Seinhart H, Greenberg G. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis 2004; 10: 220-228
39. van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003; 125: 1591-1597
40. Motley RJ, Clements D, Evans WD, Crawley EO, Evans C, Rhodes J, Compston JE. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993; 23: 95-104
41. Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M, Amor B, Couturier D. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995; 5: 156-160
42. Kanis JA. An update on the diagnosis of osteoporosis. Curr Rheumatol Rep 2000; 2: 62-66
43. Vestergaard P. Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease. Minerva Med 2004; 95: 469-480
44. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol 2004; 39: 145-153
45. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 417-422
46. Von Tirpitz C, Pischulti G, Klaus J, Rieber A, Bruckel J, Bohm BO, Adler G, Reinshagen M. Pathological bone density in chronic inflammatory bowel diseases--prevalence and risk factors. Z Gastroenterol 1999; 37: 5-12
47. Robinson RJ, Iqbal SJ, Abrams K, Al-Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther 1998; 12: 699-705
48. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997; 41: 209-214
49. D'Haens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998; 12: 419-424
50. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7: 609-614
51. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119: 639-646
52. Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994; 21: 1922-1926
53. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42: 2309-2318
54. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15: 1006-1013
55. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292-299
56. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993; 34: 1543-1546
57. Compston JE, Horton LW, Laker MF, Ayers AB, Woodhead JS, Bull HJ, Gazet JC, Pilkington TR. Bone disease after jejunoileal bypass for obesity. Lancet 1978; 2: 1-4
58. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284: 1546-1548
59. Chiba T, Isomura I, Suzuki A, Morita A. Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol 2005; 32: 199-203
60. Galun E, Flugelman MY, Rachmilewitz D. Pyoderma gangrenosum complicating ulcerative colitis: successful treatment with methylprednisolone pulse therapy and dapsone. Am J Gastroenterol 1986; 81: 988-989
61. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1821-1826
62. Fellermann K, Rudolph B, Witthoft T, Herrlinger KR, Tronnier M, Ludwig D, Stange EF. Sweet syndrome and erythema nodosum in ulcerative colitis, refractory to steroids: successful treatment with tacrolimus. Med Klin (Munich) 2001; 96: 105-108
63. Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Ophthalmol 1982; 14: 356-360
64. Fries W, Giofre MR, Catanoso M, Lo Gullo R. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol 2002; 97: 499-500
65. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123: 903-912
66. Duer RH, Targan SR, Landers CJ, LaRusso NF, Lindsay KL, Wiesner RH, Shanahan F. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100: 1385-1391
67. Stiehl A. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis. Scand J Gastroenterol Suppl 1994; 204: 59-61
68. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893
69. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95
70. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-1408
71. Rasmussen HH, Fallingborg JF, Mortensen PB, Vyberg M, Tage-Jensen U, Rasmussen SN. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 604-610
72. Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn's disease. J Clin Gastroenterol 1993; 17: 286-291
73. Barthet M, Hastier P, Bernard JP, Bordes G, Frederick J, Allio S, Mambrini P, Saint-Paul MC, Delmont JP, Salducci J, Grimaud JC, Sahel J. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol 1999; 94: 2141-2148
74. Hegnhoj J, Hansen CP, Rannem T, Sobirk H, Andersen LB, Andersen JR. Pancreatic function in Crohn's disease. Gut 1990; 31: 1076-1079
75. Herrlinger KR, Stange EF. The pancreas and inflammatory bowel diseases. Int J Pancreatol 2000; 27: 171-179
76. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000; 23: 429-448
77. Stocker W, Otte M, Ulrich S, Normann D, Finkbeiner H, Stokker K, Jantschek G, Scriba PC. Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol Suppl 1987; 139: 41-52
78. Seibold F, Weber P, Jenss H, Wiedmann KH. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 1991; 32: 1192-1197
79. Joossens S, Vermeire S, Van Steen K, Godefridis G, Claessens G, Pierik M, Vlietinck R, Aerts R, Rutgeerts P, Bossuyt X. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 771-777
80. Seibold F, Scheurlen M, Muller A, Jenss H, Weber P. Impaired pancreatic function in patients with Crohn's disease with and without pancreatic autoantibodies. J Clin Gastroenterol 1996; 22: 202-206
81. Axon AT, Ashton MG, Lintott DJ. Pancreatogram changes in patients with calculous biliary disease. Br J Surg 1979; 66: 466-470
82. Heikius B, Niemela S, Lehtola J, Karttunen T, Lahde S. Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1996; 31: 517-523
83. Angelini G, Cavallini G, Bovo P, Brocco G, Castagnini A, Lavarini E, Merigo F, Tallon N, Scuro LA. Pancreatic function in chronic inflammatory bowel disease. Int J Pancreatol 1988; 3: 185-193
84. Gschwantler M, Kogelbauer G, Klose W, Bibus B, Tscholakoff D, Weiss W. The pancreas as a site of granulomatous inflammation in Crohn's disease. Gastroenterology 1995; 108: 1246-1249
85. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99: 97-101
86. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, Grisar J, Machold K, Scholz S, Vogelsang H, Novacek G. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53: 542-548
87. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 1997; 90: 183-188
88. Vecchi M, Sacchi E, Saibeni S, Meucci G, Tagliabue L, Duca F, De Franchis R. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. Dig Dis Sci 2000; 45: 1465-1469
89. Zauber NP, Sabbath-Solitare M, Rajoria G, Mogan G. Factor V Leiden mutation is not increased in patients with inflammatory bowel disease. J Clin Gastroenterol 1998; 27: 215-216
90. Mahmud N, Molloy A, McPartlin J, Corbally R, Whitehead AS, Scott JM, Weir DG. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut 1999; 45: 389-394
91. Herrlinger KR, Cummings JR, Barnardo MC, Schwab M, Ahmad T, Jewell DP. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics 2005; 15: 705-711
92. Stokke KT, Teisberg PA, Myhre E, Hovig T, Flatmark A, Gjone E. Nephrotic syndrome in ulcerative colitis. Scand J Gastroenterol 1976; 11: 571-576
93. Glassman M, Kaplan M, Spivak W. Immune-complex glomerulonephritis in Crohn's disease. J Pediatr Gastroenterol Nutr 1986; 5: 966-969
94. Kullmann F, Kullmann M, Leser HG, Kramer BK, Riegger AJ, Scholmerich J. Nephrotic syndrome as the initial symptom of Crohn disease. Z Gastroenterol 1996; 34: 757-762
95. Dhiman RK, Poddar U, Sharma BC, Arora P, Saraswat VA, Pandey R, Naik SR. Membranous glomerulonephritis in association with ulcerative colitis. Indian J Gastroenterol 1998; 17: 62
96. Archimandritis AJ, Weetch MS. Kidney granuloma in Crohn's disease. BMJ 1993; 307: 540-541
97. Marteau P, Nelet F, Le Lu M, Devaux C. Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996; 10: 949-956
98. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-539
99. Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004; 126: 1733-1739
100. Kreisel W, Wolf LM, Grotz W, Grieshaber M. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8: 461-468
101. Fraser JS, Muller AF, Smith DJ, Newman DJ, Lamb EJ. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther 2001; 15: 1131-1137
102. Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stange EF. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 2001; 15: 363-369
103. Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993; 72: 151-183
104. Kraft SC, Earle RH, Roesler M, Esterly JR. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch Intern Med 1976; 136: 454-459
105. Fireman Z, Osipov A, Kivity S, Kopelman Y, Sternberg A, Lazarov E, Fireman E. The use of induced sputum in the assessment of pulmonary involvement in Crohn's disease. Am J Gastroenterol 2000; 95: 730-734
106. Wallaert B, Colombel JF, Tonnel AB, Bonniere P, Cortot A, Paris JC, Voisin C. Evidence of lymphocyte alveolitis in Crohn's disease. Chest 1985; 87: 363-367
107. Herrlinger KR, Noftz MK, Dalhoff K, Ludwig D, Stange EF, Fellermann K. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol 2002; 97: 377-381
108. Songur N, Songur Y, Tuzun M, Dogan I, Tuzun D, Ensari A, Hekimoglu B. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol 2003; 37: 292-298
109. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2003; 9: 104-115
110. Vandenplas O, Casel S, Delos M, Trigaux JP, Melange M, Marchand E. Granulomatous bronchiolitis associated with Crohn's disease. Am J Respir Crit Care Med 1998; 158: 1676-1679
111. Bewig B, Manske I, Bottcher H, Bastian A, Nitsche R, Folsch UR. Crohn's disease mimicking sarcoidosis in bronchoalveolar lavage. Respiration 1999; 66: 467-469
112. Smiejan JM, Cosnes J, Chollet-Martin S, Soler P, Basset FM, Le Quintrec Y, Hance AJ. Sarcoid-like lymphocytosis of the lower respiratory tract in patients with active Crohn's disease. Ann Intern Med 1986; 104: 17-21
113. Fellermann K, Stahl M, Dahlhoff K, Amthor M, Ludwig D, Stange EF. Crohn's disease and sarcoidosis: systemic granulomatosis? Eur J Gastroenterol Hepatol 1997; 9: 1121-1124
114. Mahadeva R, Walsh G, Flower CD, Shneerson JM. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J 2000; 15: 41-48
115. Williams T, Eidus L, Thomas P. Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy. Chest 1982; 81: 766-768
116. Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. Eur Respir J 2002; 19: 756-764
117. Tanigawa K, Sugiyama K, Matsuyama H, Nakao H, Kohno K, Komuro Y, Iwanaga Y, Eguchi K, Kitaichi M, Takagi H. Mesalazine-induced eosinophilic pneumonia. Respiration 1999; 66: 69-72
118. Ekbom A, Helmick CG, Zack M, Holmberg L, Adami HO. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 1992; 103: 954-960
119. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003; 125: 1576-1582
120. Persson PG, Bernell O, Leijonmarck CE, Farahmand BY, Hellers G, Ahlbom A. Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 1996; 110: 1339-1345
121. Satsangi J. Allez, Extra-intestinal manifetations of inflammatory bowel disease: others., in Inflammatory bowel disease, S.L.R. Churchill Livingstone 2003: 591-697
122. Sadovnick AD, Paty DW, Yannakoulias G. Concurrence of multiple sclerosis and inflammatory bowel disease. N Engl J Med 1989; 321: 762-763
123. Rang EH, Brooke BN, Hermon-Taylor J. Association of ulcerative colitis with multiple sclerosis. Lancet 1982; 2: 555
124. Kimura K, Hunter SF, Thollander MS, Loftus EV Jr, Melton LJ 3rd, O'Brien PC, Rodriguez M, Phillips SF. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc 2000; 75: 802-806
125. Purrmann J, Arendt G, Cleveland S, Borchard F, Furst W, Gemsa R, Bertrams J, Hengels KJ. Association of Crohn's disease and multiple sclerosis. Is there a common background? J Clin Gastroenterol 1992; 14: 43-46
126. Lossos A, River Y, Eliakim A, Steiner I. Neurologic aspects of inflammatory bowel disease. Neurology 1995; 45: 416-421
127. Sedwick LA, Klingele TG, Burde RM, Behrens MM. Optic neuritis in inflammatory bowel disease. J Clin Neuroophthalmol 1984; 4: 3-6
128. Nemni R, Fazio R, Corbo M, Sessa M, Comi G, Canal N. Peripheral neuropathy associated with Crohn's disease. Neurology 1987; 37: 1414-1417
129. Bachmeyer C, Leclerc-Landgraf N, Laurette F, Coutarel P, Cadranel JF, Medioni J, Dhote R, Mougeot-Martin M. Acute autoimmune sensorineural hearing loss associated with Crohn's disease. Am J Gastroenterol 1998; 93: 2565-2567
130. Akbayir N, Calis AB, Alkim C, Sokmen HM, Erdem L, Ozbal A, Bolukbas F, Akbayir N. Sensorineural hearing loss in patients with inflammatory bowel disease: a subclinical extraintestinal manifestation. Dig Dis Sci 2005; 50: 1938-1945
131. Geissler A, Andus T, Roth M, Kullmann F, Caesar I, Held P, Gross V, Feuerbach S, Scholmerich J. Focal white-matter lesions in brain of patients with inflammatory bowel disease. Lancet 1995; 345: 897-898
132. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005; 129: 819-826
133. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381
134. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-368
135. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-2869
136. Mejico LJ. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol 2004; 122: 793-794
137. Thomas CW Jr, Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004; 10: 28-31